Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28339538 | 1.00 | SMN1; SMN2 (0.61) | SMN1; SMN2HTTL3MBTL1CYP2D6POLB | |
| SCHEMBL27038904 | 0.89 | CHRM4 (0.51) | SMN1; SMN2HTTL3MBTL1CYP2D6POLB | |
| SCHEMBL4201270 | 0.89 | CHRM4 (0.51) | SMN1; SMN2HTTL3MBTL1CYP2D6POLB | |
| SCHEMBL23931262 | 0.89 | CHRM4 (0.51) | SMN1; SMN2HTTL3MBTL1CYP2D6POLB | |
| SCHEMBL6206557 | 0.83 | SMN1; SMN2 (0.63) | SMN1; SMN2HTTL3MBTL1CYP2D6POLB | |
| SCHEMBL689750 | 0.83 | SMN1; SMN2 (0.63) | SMN1; SMN2HTTL3MBTL1CYP2D6POLB | |
| SCHEMBL13003548 | 0.83 | SMN1; SMN2 (0.63) | SMN1; SMN2HTTL3MBTL1CYP2D6POLB | |
| Hydrochloric Acid SCHEMBL32671816 | 0.80 | SMN1; SMN2 (0.64) | SMN1; SMN2HTTL3MBTL1CYP2D6POLB | |
| SCHEMBL21873695 | 0.80 | — | — | |
| SCHEMBL28999414 | 0.79 | ATM (0.43) | SMN1; SMN2ATMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110637015-A | Farnesoin X receptor agonists and uses thereof | 梅塔科林公司 | 2019-12-31 | — | — | CN | claimed |
| WO-2024017358-A1 | MACROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 贝达药业股份有限公司 | 2024-01-25 | — | — | WO | disclosed |
| US-20100331546-A1 | METHOD FOR OPTICAL RESOLUTION OF ALKYL PIPERIDIN-3-YL CARBAMATE AND INTERMEDIATE THEREFOR | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-12-30 | — | — | US | disclosed |
| EP-2248803-A1 | METHOD FOR OPTICAL RESOLUTION OF ALKYLPIPERIDIN-3-YL CARBAMATE AND INTERMEDIATE THEREFOR | Sumitomo Chemical Company, Limited (JP) | 2010-11-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331546-A1 | METHOD FOR OPTICAL RESOLUTION OF ALKYL PIPERIDIN-3-YL CARBAMATE AND INTERMEDIATE THEREFOR | FAR1, NOTUM, CYP51A1 | SMN1; SMN2 4735/4885HTT 987/4885L3MBTL1 2902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.